---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019405"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:20:49.079142+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix preliminary Q3 revenue $10.6M-$11.2M, core lung diagnostics up 96-103% YoY

## Summary
- Total Q3 2022 revenue estimated $10.6M-$11.2M, up 62-71% YoY.
- Core lung diagnostic testing revenue $8.9M-$9.2M, a 96-103% increase YoY.
- COVID testing revenue $1.1M-$1.3M, up 117-157% YoY; expects immaterial in Q4.
- Biopharma services revenue $0.6M-$0.7M, down 53-60% YoY due to clinical study delays.
- Cash and equivalents $15.2M as of Sep 30; expects FY2022 revenue near high end of $37.5M-$39.5M guidance range.

## SEC filing metadata
- accession: 0000950170-22-019405
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022019405/0000950170-22-019405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022019405/bdsx-20221011.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019405
- JSON: https://secwatch.observer/filing/0000950170-22-019405.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.